Compare Adaptive Biotechnologies Corp (ADPT) vs Quanta Services Inc (PWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Quanta Services Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Quanta Services Inc trades at $661.6 (market cap $98.56B). The key difference: Quanta Services Inc is far larger — about 29.6× Adaptive Biotechnologies Corp's market cap, and Quanta Services Inc pays a 0.07% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PWR | |
|---|---|---|
Market Cap | $3.33B | $98.56B |
Sector | Health | Industrials |
52-Week High | $22.37 | $785.24 |
52-Week Low | $10.24 | $372.50 |
Enterprise Value | $3.19B | $104.51B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Quanta Services (PWR) trades at $656.79, down 1.72% amid bearish technical signals, though it maintains strong analyst support with 27 buy ratings. The company shows robust revenue growth, reaching $28.48B in 2025, with consistent earnings beats in recent quarters. However, premium valuation metrics including a P/E of 92.46 and EV/EBITDA of 39.58 present challenges. Recent news highlights infrastructure demand drivers but questions valuation sustainability after a 79% yearly gain.
PWR's outlook is supported by record backlog and infrastructure spending tailwinds, but execution risks and high valuation create near-term headwinds. The consensus price target of $842.67 suggests 28% upside potential, though investors must weigh growth prospects against current premium multiples and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
